Serum heparan sulfate concentration is correlated with the failure of epidermal growth factor receptor tyrosine kinase inhibitor treatment in patients with lung adenocarcinoma

Journal of Thoracic Oncology

Volumn 6, Issue 11, 2011, Pages 1889-1894

  Nishio, Makoto ^a   Yamanaka, Takeharu ^b   Matsumoto, Kazuko ^c   Kimura, Hideharu ^c   Sakai, Kazuko ^c   Sakai, Asao ^d   Sone, Takashi ^d   Horiike, Atsushi ^a   Koizumi, Fumiaki ^e   Kasahara, Kazuo ^d   Ohira, Tatsuo ^f   Ikeda, Norihiko ^f   Saijo, Nagahiro ^c   Arao, Tokuzo ^c   Nishio, Kazuto ^c  

^a CANCER INSTITUTE HOSPITAL   (Japan)

^b NATIONAL KYUSHU CANCER CENTER   (Japan)

^c KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d KANAZAWA UNIVERSITY   (Japan)

^e NATIONAL CANCER CENTER HOSPITAL   (Japan)

^f TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

EGFRtyrosine kinase inhibitors; Heparan sulfate; Non small cell lung cancer

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; GROWTH FACTOR RECEPTOR; HEPARAN SULFATE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; CONTROLLED STUDY; CORRELATION COEFFICIENT; DISEASE COURSE; DRUG TREATMENT FAILURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE ACTIVATION; GENE MUTATION; HUMAN; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROPORTIONAL HAZARDS MODEL; RECEPTOR GENE; RETROSPECTIVE STUDY; SEX DIFFERENCE; SIGNAL TRANSDUCTION; SMOKING; STATISTICAL SIGNIFICANCE; TREATMENT RESPONSE; UNIVARIATE ANALYSIS;

EID: 80054923455     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3182286d41     Document Type: Article

References (33)

1. Bishop JR, Schuksz M, Esko JD. Heparan sulphate proteoglycans fine-tune mammalian physiology. Nature 2007;446:1030-1037. (Pubitemid 46676065)
2. Coombe DR, Kett WC. Heparan sulfate-protein interactions: therapeutic potential through structure-function insights. Cell Mol Life Sci 2005;62: 410-424. (Pubitemid 40385034)
3. Sasisekharan R, Shriver Z, Venkataraman G, et al. Roles of heparan-sulphate glycosaminoglycans in cancer. Nat Rev Cancer 2002;2:521-528. (Pubitemid 37328933)
4. Mohammadi M, Olsen SK, Ibrahimi OA. Structural basis for fibroblast growth factor receptor activation. Cytokine Growth Factor Rev 2005; 16:107-137. (Pubitemid 40616111)
5. Pellegrini L. Role of heparan sulfate in fibroblast growth factor signalling: a structural view. Curr Opin Struct Biol 2001;11:629-634. (Pubitemid 32972028)
6. Ciardiello F, Caputo R, Tortora G, et al. Antitumor effect and potenti-ation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 2000;6:2053-2063. (Pubitemid 30305105)
7. Moasser MM, Basso A, Averbuch SD, et al. The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res 2001;61:7184-7188. (Pubitemid 32946513)
8. Koizumi F, Kanzawa F, Nishio K, et al. Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib ("Iressa") and the DNA topoisomerase I inhibitor CPT-11 (irinotecan) in human colorectal cancer cells. Int J Cancer 2004;108:464-472. (Pubitemid 37549614)
9. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005;366:1527-1537. (Pubitemid 41540110)
10. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353: 123-132. (Pubitemid 41058344)
11. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol 2003;21:2237-2246. (Pubitemid 46621858)
12. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139. (Pubitemid 38637993)
13. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304: 1497-1500. (Pubitemid 38720929)
14. John T, Liu G, Tsao MS. Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors. Oncogene 2009;28(Suppl 1):S14-S23.
15. Mitsudomi T, Morita S, Yatabe Y, et al.; for the West Japan Oncology Group. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010;11:121-128.
16. Maemondo M, Inoue A, Kobayashi K, et al. North-East Japan Study Group. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362:2380-2388.
17. Kasahara K, Arao T, Sakai K, et al. Impact of serum hepatocyte growth factor on treatment response to epidermal growth factor receptor ty-rosine kinase inhibitors in patients with non-small cell lung adenocar-cinoma. Clin Cancer Res 2010;16:4616-4624.
18. Kleinbaum DG, Klein M. Survival Analysis: A Self-Learning Text. New York: Springer, 2005. Pp. 257-452.
19. Lu H, McDowell LM, Studelska DR, et al. Glycosaminoglycans in human and bovine serum: detection of twenty-four heparan sulfate and chondroitin sulfate motifs including a novel sialic acid-modified chondroitin sulfate linkage hexasaccharide. Glycobiol Insights 2010;2010:13-28.
20. Björnsson S. Quantitation of proteoglycans as glycosaminoglycans in biological fluids using an Alcian blue dot blot analysis. Anal Biochem 1998;256:229-237. (Pubitemid 28106736)
21. Vavetsi R, Bonovas S, Polizou P, et al. The diagnostic role of glycos-aminoglycans in pleural effusions: a pilot study. BMC Pulm Med 2009;9:9.
22. Pothacharoen P, Siriaunkgul S, Ong-Chai S, et al. Raised serum chon-droitin sulfate epitope level in ovarian epithelial cancer. J Biochem 2006;140:517-524. (Pubitemid 44870916)
23. Aviezer D, Hecht D, Safran M, et al. Perlecan, basal lamina proteogly-can, promotes basic fibroblast growth factor-receptor binding, mitogen-esis, and angiogenesis. Cell 1994;79:1005-1013.
24. Roskams T, De Vos R, David G, et al. Heparan sulphate proteoglycan expression in human primary liver tumours. J Pathol 1998;185:290-297. (Pubitemid 28320051)
25. Guelstein VI, Tchypysheva TA, Ermilova VD, et al. Myoepithelial and basement membrane antigens in benign and malignant human breast tumors. Int J Cancer 1993;53:269-277. (Pubitemid 23042878)
26. Jiang X, Couchman JR. Perlecan and tumor angiogenesis. J Histochem Cytochem 2003;51:1393-1410. (Pubitemid 37444529)
27. Seidel C, Sundan A, Hjorth M, et al. Serum syndecan-1: a new independent prognostic marker in multiple myeloma. Blood 2000;95:388-392. (Pubitemid 30041645)
28. Joensuu H, Anttonen A, Eriksson M, et al. Soluble syndecan-1 and serum basic fibroblast growth factor are new prognostic factors in lung cancer. Cancer Res 2002;62:5210-5217. (Pubitemid 35024592)
29. Yang Y, Yaccoby S, Liu W, et al. Soluble syndecan-1 promotes growth of myeloma tumors in vivo. Blood 2002;100:610-617. (Pubitemid 34761126)
30. Sanderson RD, Yang Y, Kelly T, et al. Enzymatic remodeling of heparan sulfate proteoglycans within the tumor microenvironment: growth regulation and the prospect of new cancer therapies. J Cell Biochem 2005;96:897-905. (Pubitemid 41688716)
31. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316:1039-1043. (Pubitemid 46799492)
32. Yano S, Wang W, Li Q, et al. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res 2008;68:9479-9487.
33. Turke AB, Zejnullahu K, Wu YL, et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 2010;17:77-88.